Biocon Settles Roche's US Patent Lawsuit Over Proposed Breast-Cancer Biosimilar
Biocon said it settled Genentech's US lawsuit over its proposed biosimilar of the breast-cancer drug Perjeta.
Biocon said Wednesday that it had settled a US lawsuit brought by Roche's Genentech over Biocon's proposed biosimilar version of Perjeta, Genentech's blockbuster breast-cancer drug. The case is Genentech Inc v. Biocon Biologics Inc, US District Cour…